Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2017)

Spero Therapeutics' Income from Non-Controlling Interests history spans 2 years, with the latest figure at -$6000.0 for Q4 2017.

  • For Q4 2017, Income from Non-Controlling Interests rose 99.39% year-over-year to -$6000.0; the TTM value through Dec 2017 reached -$1.1 million, changed N/A, while the annual FY2017 figure was -$1.1 million, 84.01% up from the prior year.
  • Income from Non-Controlling Interests reached -$6000.0 in Q4 2017 per SPRO's latest filing, up from -$8000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$6000.0 in Q4 2017 to a low of -$1.6 million in Q3 2016.